It's over for the 405 million doses pre-ordered by the European Union of the European vaccine against the coronavirus.
The German laboratory CureVac announced on Tuesday the abandonment of the development of its first candidate vaccine against Covid-19, initially hopeful but whose effectiveness has proved disappointing.
The final results of its large-scale clinical study, published in early July, showed only 48% effectiveness.
Nevertheless, in agreement with Brussels and the British laboratory GSK, CureVac will now work on a second generation vaccine, more promising.
"The global fight against Covid-19 continues and we are determined to make a decisive contribution to it with a safe and effective vaccine" but "the requirements for an effective fight against the virus and the variants that appear have changed", explained Franz -Werner Haas, boss of CureVac, in a statement.
World
Covid-19: South Africa seeks to develop continent's first messenger RNA vaccine
World
Coronavirus in the United Kingdom: A very harsh parliamentary report on Boris Johnson's management of the pandemic
Delta variant
Laboratory
Coronavirus
Covid 19
Anti-covid vaccine
Health
EU
Germany